NCT06504225招募中不适用
Long-term Evaluation of the Value of Using an MTor Inhibitor (everolimus) for the Minimisation of Anticalceurins in Old-for-old Kidney Transplantation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 260
- 试验地点
- 14
- 主要终点
- Patient survival
研究概览
简要总结
Long Term Follow up of EVEROLD study
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed patients participating to the EVEROLD study
- •Patient having completed the EVEROLD M12 follow-up visit
- •Patient agreeing to participate in the observational study
排除标准
- •Opposition to the use his medical data
- •Patient under legal protection
结局指标
主要结局
Patient survival
时间窗: up to 12 years
Patient survival at last follow-up
Graft survival
时间窗: up to 12 years
Graft survival at last follow-up
次要结局
- Major cardiovascular events(up to 12 years)
- Rejection rate(up to 12 years)
- Infection rate(up to 12 years)
- Hospitalization(up to 12 years)
- eGFR(up to 12 years)
- Cancer rate(up to 12 years)
研究者
研究点 (14)
Loading locations...
相似试验
终止
3 期
A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs SyndromeRestless Legs SyndromeNCT03992196UCB Biopharma SRL10
进行中（未招募）
3 期
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)Pulmonary Arterial HypertensionPAHNCT04796337Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA815
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.EUCTR2021-002344-73-DESanofi-aventis recherche & développement315
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.EUCTR2021-002344-73-HUSanofi-aventis recherche & développement315
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.Dermatitis atopicMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-002344-73-CZSanofi-aventis recherche & développement315